Publications by authors named "Alessandro Atanasio"

Claim this Profile
C
Clinical and Prognostic Correlates of the Reticulin-Collagen-Osteosclerosis Score in Primary Myelofibrosis.
Raffaella Santi, Giacomo Coltro, Gioia Di Stefano, Alessandro Atanasio, Paolo Cicogna

Mod Pathol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Validation and molecular integration of the RR6 model to predict survival after 6 months of therapy with ruxolitinib.
Giacomo Coltro, Giulio Capecchi, Margherita Maffioli, Francesco Mannelli, Barbara Mora, Alessandro Atanasio

Haematologica· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CALR mutation burden in essential thrombocythemia and disease outcome.
Paola Guglielmelli, Natasha Szuber, Naseema Gangat, Giulio Capecchi, Chiara Maccari, Alessandro Atanasio

Blood· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
One thousand patients with essential thrombocythemia: the Florence-CRIMM experience.
Giuseppe G Loscocco, Francesca Gesullo, Giulio Capecchi, Alessandro Atanasio, Chiara Maccari

Blood Cancer J· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Testing for rare types of Hereditary Hemochromatosis. A genetic study of two Italian families affected by early onset iron overload.
Alessandro Atanasio, Sara Bernabini, Angela Consagra, Irene Giotti, Valentina Carrai

Int J Lab Hematol· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phenotypic correlations of CALR mutation variant allele frequency in patients with myelofibrosis.
Paola Guglielmelli, Chiara Maccari, Benedetta Sordi, Manjola Balliu, Alessandro Atanasio

Blood Cancer J· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Differential prognostic impact of cytopenic phenotype in prefibrotic vs overt primary myelofibrosis.
Giacomo Coltro, Francesco Mannelli, Giuseppe Gaetano Loscocco, Carmela Mannarelli, Giada Rotunno, Alessandro Atanasio

Blood Cancer J· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Compassionate use of JAK1/2 inhibitor ruxolitinib for severe COVID-19: a prospective observational study.
Alessandro M Vannucchi, Benedetta Sordi, Alessandro Morettini, Carlo Nozzoli, Loredana Poggesi, Alessandro Atanasio

Leukemia· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis